Novavax, Inc. NVAX on Tuesday launched preliminary outcomes from the SHIELD-Utah research investigating the consequences of systemic and native reactogenicity of COVID-19 vaccine doses in Utah.
SHIELD-Utah was a potential, interventional research performed on the College of Utah Well being.
The research confirmed Novavax’s COVID-19 Vaccine, Adjuvanted (2024-2025 Components), focusing on the JN.1 pressure, resulted in fewer and fewer extreme reactogenicity signs in comparison with the Pfizer Inc PFE–BioNTech SE’s BNTX mRNA 2024-2025 vaccine.
Additionally Learn: Regardless of Headwinds, Biotech Promote-Off May Provide Shopping for Alternative: Analyst
This real-world research, performed between September and December 2024, additionally confirmed that the influence of signs on day by day actions, together with work and household duties, was decrease in recipients of Novavax’s vaccine.
“The danger of negative effects or reactogenicity has been proven to be a significant choice issue for these opting to get vaccinated. Our findings of decrease frequency and depth of reactogenicity signs from the protein-based COVID-19 vaccine noticed in SHIELD-Utah add worthwhile insights to the general public debate weighing alternative and worth of COVID-19 vaccination,” mentioned Sarang Okay. Yoon, DO, MOH, Principal Investigator, College of Utah Well being.
As in earlier research, the SHIELD research discovered well being care staff who obtained the Novavax vaccine reported considerably fewer reactogenicity occasions than Pfizer-BioNTech recipients.
On common, Novavax recipients skilled 1.7 signs versus 2.8 systemic signs in Pfizer-BioNTech recipients.
43.8% of Pfizer-BioNTech recipients skilled a minimum of one symptom of Grade 2 or larger in comparison with 24.2% of Novavax recipients.
Native reactogenicity occasions additionally confirmed an absolute distinction of 12.5% fewer in Novavax recipients versus Pfizer-BioNTech recipients.
The influence of signs on day by day actions, together with work, confirmed the hours of lowered exercise had been decrease in Novavax recipients versus Pfizer-BioNTech recipients (imply=0.7 vs. 1.4h and imply=0.8 vs. 2.4h for missed work and fewer productiveness, respectively).
Earlier this month, the regulators missed the deadline for deciding to grant full approval to Novavax’s COVID-19 shot.
Value Motion: NVAX inventory is down 3.60% at $6.18 on the final verify Tuesday
Learn Subsequent:
Picture: Shutterstock
Market Information and Knowledge delivered to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
